Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.09, FiscalAI reports. The business had revenue of $7.17 million during the quarter, compared to the consensus estimate of $5.29 million. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%.
Sonoma Pharmaceuticals Stock Up 0.9%
Shares of NASDAQ:SNOA traded up $0.01 during trading on Tuesday, hitting $1.14. 89,800 shares of the company were exchanged, compared to its average volume of 113,565. Sonoma Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $3.95. The company has a market capitalization of $5.46 million, a P/E ratio of -0.93 and a beta of 1.31. The business’s 50 day moving average is $1.21 and its 200-day moving average is $1.66.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Get Our Latest Stock Report on SNOA
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment. The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions. Products marketed under the company’s brands have included Dermacyn, for wound and skin care, and Ocucyn, for ophthalmic care, along with veterinary products and other prescription and over-the-counter formulations.
Further Reading
- Five stocks we like better than Sonoma Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
